Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Top Cited Papers
- 14 April 2005
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 434 (7035) , 913-917
Abstract
The discovery that BRCA1/2 mutant cells (defective in the homologous recombination pathway of DNA repair) are spectacularly sensitive to inhibition of the enzyme PARP (involved in base excision repair) suggests a new, low toxicity, approach to the treatment of women with breast cancers caused by BRCA mutations. As the PARP inhibitors have no effect on cells with functional homologous recombination, the hope is that the treatment will be specific for breast cancer cells. PARP-inhibiting chemotherapeutics may be able to make use of a ‘synthetic lethal’ effect as an alternative to conventional nonspecific cytotoxic anticancer treatments. Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage1,2,3. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours4. Here, we show that PARP inhibitors trigger γ-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.Keywords
This publication has 26 references indexed in Scilit:
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forksOncogene, 2004
- Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 InhibitorsJournal of Medicinal Chemistry, 2002
- Brca2 (XRCC11) Deficiency Results in Radioresistant DNA Synthesis and a Higher Frequency of Spontaneous DeletionsMolecular and Cellular Biology, 2002
- DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells11Edited by J. KarnJournal of Molecular Biology, 2001
- Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaksTrends in Biochemical Sciences, 1995
- Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene.Proceedings of the National Academy of Sciences, 1995
- Instability and decay of the primary structure of DNANature, 1993
- Direct stimulation of poly(ADP ribose) polymerase in permeabilized cells by double-stranded DNA oligomersAnalytical Biochemistry, 1991
- Poly(ADP‐ribose) polymerase activity in nucleotide permeable cellsFEBS Letters, 1978